Baseline characteristics of patients
| . | RT* (n = 9) . | CLL (n = 16) . | Total (n = 25) . |
|---|---|---|---|
| Age, y | |||
| Median | 69 | 72 | 69 |
| Range | (46-78) | (59-81) | (46-81) |
| ≥70 | 4 (44) | 9 (56) | 13 (52) |
| Sex, no. (%) | |||
| Male | 7 (78) | 10 (63) | 17 (68) |
| Female | 2 (22) | 6 (38) | 8 (32) |
| Race, white | 9 (100) | 16 (100) | 25 (100) |
| ECOG performance score, no. (%) | |||
| 0 | 3 (33) | 2 (13) | 5 (20) |
| 1 | 5 (56) | 12 (75) | 17 (68) |
| 2 | 1 (11) | 2 (13) | 3 (12) |
| Rai stage, no. (%) | |||
| 0-2 (low) | 3 (33) | 3 (19) | 6 (24) |
| 3-4 (high) | 6 (67) | 13 (81) | 19 (76) |
| CLL FISH,† no. (%) | |||
| del(17p)/-17 | 3 (33) | 6 (38) | 9 (36) |
| TP53+, no del(17p) | 2 (22) | 1 (6) | 3 (12) |
| del(11q) | 0 | 4 (25) | 4 (16) |
| +12 | 0 | 2 (13) | 2 (8) |
| del(13q) | 1 (11) | 2 (13) | 3 (12) |
| Normal | 3 (33) | 1 (6) | 4 (16) |
| IGHV, no. (%) | |||
| Mutated | 2 (22) | 2 (13) | 4 (16) |
| Unmutated | 7 (78) | 14 (88) | 21 (84) |
| Previous therapies, no. (%) | |||
| Median | 5 | 3.5 | 4 |
| Range | (1,10) | (1,9) | (1,10) |
| Prior alkylator | 8 (89) | 16 (100) | 24 (96) |
| Prior anti-CD20 | 8 (89) | 16 (100) | 24 (96) |
| Prior purine analog | 5 (56) | 13 (81) | 18 (72) |
| Prior anthracycline | 6 (67) | 6 (38) | 12 (48) |
| Prior ibrutinib | 6 (67) | 9 (56) | 15 (60) |
| Progression on ibrutinib/idelalisib | 6 (67) | 6 (38) | 12 (48) |
| . | RT* (n = 9) . | CLL (n = 16) . | Total (n = 25) . |
|---|---|---|---|
| Age, y | |||
| Median | 69 | 72 | 69 |
| Range | (46-78) | (59-81) | (46-81) |
| ≥70 | 4 (44) | 9 (56) | 13 (52) |
| Sex, no. (%) | |||
| Male | 7 (78) | 10 (63) | 17 (68) |
| Female | 2 (22) | 6 (38) | 8 (32) |
| Race, white | 9 (100) | 16 (100) | 25 (100) |
| ECOG performance score, no. (%) | |||
| 0 | 3 (33) | 2 (13) | 5 (20) |
| 1 | 5 (56) | 12 (75) | 17 (68) |
| 2 | 1 (11) | 2 (13) | 3 (12) |
| Rai stage, no. (%) | |||
| 0-2 (low) | 3 (33) | 3 (19) | 6 (24) |
| 3-4 (high) | 6 (67) | 13 (81) | 19 (76) |
| CLL FISH,† no. (%) | |||
| del(17p)/-17 | 3 (33) | 6 (38) | 9 (36) |
| TP53+, no del(17p) | 2 (22) | 1 (6) | 3 (12) |
| del(11q) | 0 | 4 (25) | 4 (16) |
| +12 | 0 | 2 (13) | 2 (8) |
| del(13q) | 1 (11) | 2 (13) | 3 (12) |
| Normal | 3 (33) | 1 (6) | 4 (16) |
| IGHV, no. (%) | |||
| Mutated | 2 (22) | 2 (13) | 4 (16) |
| Unmutated | 7 (78) | 14 (88) | 21 (84) |
| Previous therapies, no. (%) | |||
| Median | 5 | 3.5 | 4 |
| Range | (1,10) | (1,9) | (1,10) |
| Prior alkylator | 8 (89) | 16 (100) | 24 (96) |
| Prior anti-CD20 | 8 (89) | 16 (100) | 24 (96) |
| Prior purine analog | 5 (56) | 13 (81) | 18 (72) |
| Prior anthracycline | 6 (67) | 6 (38) | 12 (48) |
| Prior ibrutinib | 6 (67) | 9 (56) | 15 (60) |
| Progression on ibrutinib/idelalisib | 6 (67) | 6 (38) | 12 (48) |